Sunshine Guojian Pharmaceutical Clinical Trials

Company details

Status: Public
HQ: FORT LAUDERDALE, FL, CN
Programs: 165
Drugs: 80
Patents: 121

All projects Drug pipeline Patents News & analysis

Recent trial activity

8 updates

Latest clinical program signals indexed for Sunshine Guojian Pharmaceutical.

Trial registry

184 studies

NCT01805648
rhTPO

Phase 3 active small_molecule

Thrombocytopenia

CT.gov ↗
NCT02356419
Recombinant erythropoietin stimulating protein

Phase 1 active small_molecule

Chronic Renal Failure

CT.gov ↗
NCT02460393
Humanized TNFα monoclonal antibody

Phase 1 completed small_molecule

Rheumatoid Arthritis

CT.gov ↗
NCT02522975
EPIAO®

Approved terminated small_molecule

Renal Anaemia

CT.gov ↗
NCT02947438
EPREX®

Phase 3 completed small_molecule

Renal Anemia

CT.gov ↗
NCT03019458
MINGO

Unknown completed other

X-Linked Dystonia Parkinsonism

CT.gov ↗
NCT03092102
HEC585

Phase 2 active small_molecule

Idiopathic Pulmonary Fibrosis

CT.gov ↗
NCT03097965
PROGRAM

Unknown completed other

Obesity

CT.gov ↗
NCT03125876
CT053PTSA

Phase 1 terminated small_molecule

Acute Myeloid Leukemia (AML)

CT.gov ↗
NCT03356158
CPGJ602

Phase 2 active small_molecule

Metastatic Colorectal Cancer

CT.gov ↗
NCT03388515
SSS11

Phase 1 active mab

Gout

CT.gov ↗
NCT03458481
SOF

Phase 3 completed small_molecule

Chronic HCV Infection

CT.gov ↗
NCT03462173
yimitasvir

Phase 1 completed small_molecule

Chronic Hepatitis c

CT.gov ↗
NCT03487107
SOF

Phase 3 completed small_molecule

Chronic HCV Infection

CT.gov ↗
NCT03502902
HEC 68498

Phase 1 completed small_molecule

Idiopathic Pulmonary Fibrosis

CT.gov ↗
NCT03638076
GLS4

Phase 2 completed small_molecule

Chronic Hepatitis B

CT.gov ↗
NCT03655873
HEC30654AcOH capsule

Phase 1 completed small_molecule

Healthy

CT.gov ↗
NCT03662568
GLS4

Phase 2 completed small_molecule

Chronic Hepatitis B

CT.gov ↗
NCT03663686
Litapiprant Tablet

Phase 1 completed small_molecule

Asthma

CT.gov ↗
NCT03673215
Recombinant human thrombopoietin

Phase 1 active small_molecule

Liver Cirrhosis

CT.gov ↗
NCT03673696
HEC74647PA capsule

Phase 1 completed small_molecule

Chronic Hepatitis C

CT.gov ↗
NCT03758287
CT053PTSA

Phase 2 completed small_molecule

Non-small Cell Lung Cancer

CT.gov ↗
NCT03811678
Kangdaprevir Sodium Tablet

Phase 1 completed small_molecule

Chronic Hepatitis c

CT.gov ↗
NCT03876925
CT053PTSA

Phase 2 terminated small_molecule

Renal Cell Cancer Metastatic

CT.gov ↗
NCT03886688
HEC53856

Phase 1 completed small_molecule

Healthy

CT.gov ↗
NCT03888092
Z650

Phase 2 completed small_molecule

Esophageal Squamous Cell Carcinoma

CT.gov ↗
NCT03903081
HEC110114 tablet

Phase 2 completed small_molecule

Chronic Hepatitis C

CT.gov ↗
NCT03943251
HEC113995PA•H2O tablet

Phase 1 completed small_molecule

Healthy

CT.gov ↗
NCT03950297
609A

Phase 1 active small_molecule

Solid Tumors

CT.gov ↗
NCT03950687
Recombinant Human Erythropoiesis Injection (CHO cell)

Phase 2 active small_molecule

Chronic Renal Failure With Hemodialysis

CT.gov ↗
NCT03980379
304 injection

Phase 1 active small_molecule

CD20 Positive B Cell NHL

CT.gov ↗
NCT03998345
609A

Phase 1 active small_molecule

Solid Tumors

CT.gov ↗
NCT04047394
PEGylated recombinant candida urate oxidase

Phase 1 active small_molecule

Gout

CT.gov ↗
NCT04079374
Etanercept

Phase 3 active small_molecule

Rheumatoid Arthritis

CT.gov ↗
NCT04089267
TPO

Approved completed small_molecule

ITP

CT.gov ↗
NCT04131192
Z650

Phase 1 terminated small_molecule

Pancreatic Cancer

CT.gov ↗
NCT04147208
GLS4

Phase 2 completed small_molecule

Chronic HBV Infection

CT.gov ↗
NCT04151407
Drug 601

Phase 1 active small_molecule

Diabetic Macular Edema

CT.gov ↗
NCT04194242
HEC96719 tablets

Phase 1 completed small_molecule

Nonalcoholic Steatohepatitis (NASH)

CT.gov ↗
NCT04201275
HEC74647PA capsule

Phase 1 completed small_molecule

Chronic Hepatitis C

CT.gov ↗
NCT04202952
HEC110114 tablet

Phase 2 completed small_molecule

Chronic Hepatitis C

CT.gov ↗
NCT04232514
HEC74647

Phase 1 completed small_molecule

Chronic Hepatitis C

CT.gov ↗
NCT04317833
SSS17

Phase 1 active small_molecule

Anemia in Chronic Kidney Diseases

CT.gov ↗
NCT04324372
HEC68498

Phase 1 completed small_molecule

Advanced Refractory Solid Tumors

CT.gov ↗
NCT04345458
prefilled liquid etanercept(Yisaipu)

Phase 3 completed small_molecule

Ankylosing Spondylitis

CT.gov ↗
NCT04367441
608

Phase 1 active small_molecule

Moderate to Severe Plaque Psoriasis

CT.gov ↗
NCT04415853
Lerotinib

Phase 3 active small_molecule

Esophageal Cancer

CT.gov ↗
NCT04422496
HEC96719

Phase 1 completed small_molecule

Non-alcoholic Fatty Liver Disease

CT.gov ↗
NCT04445038
610

Phase 1 active small_molecule

add-on Maintenance Treatment of Patients With Severe Eosinophilic Asthma

CT.gov ↗
NCT04466254
CPGJ602

Phase 2 active small_molecule

Metastatic Colorectal Cancer

CT.gov ↗
NCT04468997
Drug 601

Phase 1 active small_molecule

Wet Age-related Macular Degeneration

CT.gov ↗
NCT04512170
HEC585

Phase 2 active small_molecule

Idiopathic Pulmonary Fibrosis

CT.gov ↗
NCT04527718
Placebo

Phase 1 completed small_molecule

Healthy

CT.gov ↗
NCT04536532
HEC121120 tablets

Phase 2 terminated small_molecule

Hepatitis B, Chronic

CT.gov ↗
NCT04546984
HEC96719

Phase 1 completed small_molecule

Nonalcoholic Steatohepatitis (NASH)

CT.gov ↗
NCT04551261
GLS4

Phase 2 completed small_molecule

Chronic Hepatitis B

CT.gov ↗
NCT04552808
Yimitasvir Phosphate

Phase 1 completed small_molecule

Hepatic Impairment

CT.gov ↗
NCT04565171
Yimitasvir Phosphate Capsule

Phase 1 completed small_molecule

Renal Impairment

CT.gov ↗
NCT04577703
CT053PTSA

Phase 1 completed small_molecule

Advanced Solid Tumors

CT.gov ↗
NCT04591301
HEC113995 PA•H2O tablets

Phase 1 completed small_molecule

Major Depressive Disorder

CT.gov ↗
NCT04596007
HEC83518 tablets

Phase 1 completed small_molecule

Insomnia

CT.gov ↗
NCT04601610
KN046 （PD-L1/CTLA4 BsAb）

Phase 2 terminated small_molecule

Advanced HCC

CT.gov ↗
NCT04623814
HEC113995

Phase 1 completed small_molecule

Major Depressive Disorder

CT.gov ↗
NCT04625361
HEC122505MsOH

Phase 1 completed small_molecule

Parkinson Disease

CT.gov ↗
NCT04667429
HEC83518

Phase 1 completed small_molecule

Insomnia

CT.gov ↗
NCT04667897
601 1.25mg

Phase 3 completed small_molecule

Branch Retinal Vein Occlusion

CT.gov ↗
NCT04667910
601 1.25mg

Phase 2 completed small_molecule

Central Retinal Vein Occlusion

CT.gov ↗
NCT04728984
Nalfurafine Hydrochloride

Phase 3 active small_molecule

Uremic Pruritus

CT.gov ↗
NCT04827069
Clifutinib Besylate

Phase 1 completed small_molecule

Acute Myeloid Leukemia

CT.gov ↗
NCT04865458
HEC89736

Phase 1 terminated small_molecule

Relapsed or Refractory B-cell Hematologic Malignancies

CT.gov ↗
NCT04893187
SSS17

Phase 1 active small_molecule

Anemia in Chronic Kidney Diseases

CT.gov ↗
NCT04922151
601

Phase 2 active small_molecule

Pathological Myopic Choroidal Neovascularization

CT.gov ↗
NCT04925661
HEC53856

Phase 1 completed small_molecule

Chronic Kidney Diseases

CT.gov ↗
NCT04925674
HEC53856

Phase 1 completed small_molecule

Hemodialysis

CT.gov ↗
NCT04982913
HEC116094

Phase 1 completed small_molecule

Influenza

CT.gov ↗
NCT04984512
Mitizodone Phosphate tablets

Phase 3 active small_molecule

Depressive Disorder, Major

CT.gov ↗
NCT04992858
CT053PTSA

Phase 2 terminated small_molecule

Advanced NSCLC

CT.gov ↗
NCT05027373
SSGJ-613

Phase 1 active small_molecule

Systemic Juvenile Idiopathic Arthritis

CT.gov ↗
NCT05048368
Larotinib

Phase 1 active small_molecule

Esophageal Cancer

CT.gov ↗
NCT05057949
Larotinib

Phase 1 completed small_molecule

Healthy Volunteers

CT.gov ↗
NCT05059743
[14C]-Larotinib

Phase 1 completed small_molecule

Healthy Adult Male Volunteers

CT.gov ↗
NCT05060822
HEC585

Phase 2 active small_molecule

Idiopathic Pulmonary Fibrosis

CT.gov ↗
NCT05109078
[14C]- Rongliflozin

Phase 1 completed small_molecule

Healthy Adult Male Volunteers

CT.gov ↗
NCT05127772
HEC93077

Phase 1 completed small_molecule

Gout

CT.gov ↗
NCT05133882
Clifutinib Besylate

Phase 2 active small_molecule

Acute Myeloid Leukemia, Adult

CT.gov ↗
NCT05138146
609A

Phase 2 active small_molecule

Sarcoma, Soft Tissue

CT.gov ↗
NCT05139719
HEC585 dose A

Phase 2 active small_molecule

Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF)

CT.gov ↗
NCT05145179
SSGJ-705

Phase 1 active small_molecule

Receptor, ErbB-2

CT.gov ↗
NCT05193201
recombinant human thrombopoietin injection

Phase 1 active small_molecule

Liver Disease Chronic

CT.gov ↗
NCT05193214
Recombinant anti-PD-1 humanized monoclonal antibody injection

Phase 2 active small_molecule

Sarcoma, Soft Tissue

CT.gov ↗
NCT05211167
Human Erythropoiesis Injection (CHO cell)

Phase 3 active small_molecule

Kidney Failure, Chronic

CT.gov ↗
NCT05224492
Sulforaphane

Approved active small_molecule

HIV Infections

CT.gov ↗
NCT05294536
Liraglutide injection,RD12014

Phase 1 completed small_molecule

Type 2 Diabetes

CT.gov ↗
NCT05374343
pyroglutamate rongliflozin capsules

Phase 1 completed small_molecule

Type 2 Diabetes

CT.gov ↗
NCT05383131
HEC585

Phase 2 active small_molecule

Idiopathic Pulmonary Fibrosis

CT.gov ↗
NCT05391360
Freethiadine tablets(part I)

Phase 1 completed small_molecule

Hepatitis B, Chronic

CT.gov ↗
NCT05395416
HEC74647PA+HEC110114

Phase 3 completed small_molecule

Chronic HCV Infection

CT.gov ↗
NCT05397379
HEC96719

Phase 2 completed small_molecule

Non-Alcoholic Steatohepatitis

CT.gov ↗
NCT05427682
pyroglutamate rongliflozin capsules

Phase 1 completed small_molecule

Diabetes Mellitus, Type 2

CT.gov ↗
NCT05446233
[14C] Antaitavir Hasophate

Phase 1 completed small_molecule

Healthy Male Subjects

CT.gov ↗
NCT05451602
HEC169096

Phase 2 active small_molecule

Advanced Solid Tumor

CT.gov ↗
NCT05454098
Clifutinib with fed state

Phase 1 completed small_molecule

Acute Myeloid Leukemia in Children

CT.gov ↗
NCT05459285
14028 injection

Phase 1 completed mab

Type 2 Diabetes

CT.gov ↗
NCT05468346
[14C]-HEC585

Phase 1 completed small_molecule

Healthy Volunteer

CT.gov ↗
NCT05492630
HEC73077 tablets

Phase 1 completed small_molecule

Diabetic Nephropathy

CT.gov ↗
NCT05497674
Rongliflozin

Phase 1 completed small_molecule

Type 2 Diabetes Mellitus

CT.gov ↗
NCT05504876
Midazolam Syrup

Phase 1 completed small_molecule

Healthy Subjects

CT.gov ↗
NCT05520177
601 1.25mg

Phase 3 completed small_molecule

Branch Retinal Vein Occlusion

CT.gov ↗
NCT05528679
610 100mg

Phase 2 active small_molecule

Asthma

CT.gov ↗
NCT05536726
608 Q2W

Phase 3 completed small_molecule

Psoriasis

CT.gov ↗
NCT05544591
611 Q2W

Phase 2 completed small_molecule

Dermatitis, Atopic

CT.gov ↗
NCT05576298
Insulin degludec injection, RD15003

Phase 1 completed mab

Type 2 Diabetes

CT.gov ↗
NCT05583838
rhTPO

Approved completed small_molecule

Previously Treated Primary Immune Thrombocytopenia

CT.gov ↗
NCT05584306
610 30mg group

Phase 1 active small_molecule

Asthma

CT.gov ↗
NCT05586074
Clifutinib

Phase 3 active small_molecule

Leukemia, Acute Myeloid (AML)

CT.gov ↗
NCT05588908
Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg

Phase 3 active small_molecule

Acute Gout

CT.gov ↗
NCT05604898
Recombinant Anti-IL-17A Humanized Monoclonal Antibody Injection

Phase 2 active small_molecule

Psoriasis

CT.gov ↗
NCT05641558
611 150mg

Phase 2 completed small_molecule

Dermatitis, Atopic

CT.gov ↗
NCT05802862
Insulin Degludec and Insulin Aspart

Phase 3 completed small_molecule

Diabetes

CT.gov ↗
NCT05865496
611

Phase 3 active small_molecule

Sinusitis

CT.gov ↗
NCT05966701
SSGJ-613

Phase 1 active small_molecule

Arthritis, Gouty

CT.gov ↗
NCT05998304
[14C] Yiqibuvir

Phase 1 completed small_molecule

Healthy Male Subjects

CT.gov ↗
NCT06035055
Ceftolozane/tazobactam

Approved active small_molecule

Bronchiectasis

CT.gov ↗
NCT06099652
611 300 mg Q2W

Phase 2 completed small_molecule

Pulmonary Disease, Chronic Obstructive

CT.gov ↗
NCT06169891
Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg

Phase 3 active small_molecule

Acute Gout

CT.gov ↗
NCT06173284
611

Phase 3 active small_molecule

Dermatitis, Atopic

CT.gov ↗
NCT06222671
608

Phase 2 active small_molecule

Axial Spondyloarthritis

CT.gov ↗
NCT06242652
608 Dose A

Phase 2 active small_molecule

Ankylosing Spondylitis

CT.gov ↗
NCT06270225
Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg

Phase 2 active small_molecule

Gout Arthritis

CT.gov ↗
NCT06299982
608 Q2W

Phase 3 active small_molecule

Plaque Psoriasis Patients

CT.gov ↗
NCT06323213
610

Phase 3 active small_molecule

Asthma

CT.gov ↗
NCT06324812
SSGJ-611-PED-AD-Ib/II-01

Phase 2 active small_molecule

Dermatitis, Atopic

CT.gov ↗
NCT06361927
SSGJ-707

Phase 2 active small_molecule

NSCLC

CT.gov ↗
NCT06390774
SSGJ-705

Phase 2 active small_molecule

Locally Advanced, Recurrent or Metastatic Malignancies

CT.gov ↗
NCT06403501
Clascoterone

Phase 3 active small_molecule

Acne Vulgaris

CT.gov ↗
NCT06412471
SSGJ-707

Phase 2 active small_molecule

First-line Advanced NSCLC Patients

CT.gov ↗
NCT06454708
Clascoterone Cream 1%

Phase 1 completed small_molecule

Acne Vulgaris

CT.gov ↗
NCT06486077
Power Line Program

Unknown completed other

Metabolic Health

CT.gov ↗
NCT06493760
SSGJ-707

Phase 2 active small_molecule

Metastatic Colorectal Cancer

CT.gov ↗
NCT06522828
SSGJ-707

Phase 2 active small_molecule

Advanced/recurrent Endometrial Cancer and Platinum-resistant Ovarian Cancer

CT.gov ↗
NCT06533605
SSGJ-706

Phase 1 active small_molecule

Advanced Solid Tumors Patients

CT.gov ↗
NCT06554847
611

Phase 3 active small_molecule

Dermatitis, Atopic

CT.gov ↗
NCT06629376
Pegylated Recombinant Candida Utilis Uricase for Injection

Phase 1 active small_molecule

Gout

CT.gov ↗
NCT06639295
611

Phase 3 active small_molecule

Sinusitis

CT.gov ↗
NCT06674525
626

Phase 1 active small_molecule

Healthy Subjects (HS)

CT.gov ↗
NCT06680947
610

Phase 3 active small_molecule

Asthma

CT.gov ↗
NCT06854276
SSS06

Phase 2 active small_molecule

Chemotherapy-induced Anemia

CT.gov ↗
NCT06944444
SSS59

Phase 1 active small_molecule

Malignant Tumors

CT.gov ↗
NCT06980272
SSGJ-707

Phase 3 active small_molecule

Advanced Non-Small Cell Lung Cancer

CT.gov ↗
NCT06993870
HBT-708

Phase 1 active small_molecule

Advanced Solid Tumors

CT.gov ↗
NCT07007936
SSS17 Capsule (6 Dose Levels)

Phase 2 active small_molecule

Postoperative Anemia

CT.gov ↗
NCT07008703
Injection of humanized nerve growth factor (NGF) antibody

Phase 2 active small_molecule

Cancer Pain

CT.gov ↗
NCT07014631
SSS17

Phase 2 completed small_molecule

Anemia in Pre-Dialysis Patients

CT.gov ↗
NCT07016490
SSGJ-709

Phase 1 active small_molecule

Advanced Malignant Tumors

CT.gov ↗
NCT07018674
Experimental

Unknown completed other

Cognitive Health

CT.gov ↗
NCT07022002
SSGJ-705

Phase 2 active small_molecule

Locally Advanced, Recurrent or Metastatic Malignancies

CT.gov ↗
NCT07024888
SSS17

Phase 1 completed small_molecule

Healthy Subjects (HS)

CT.gov ↗
NCT07025915
[14C]SSS17

Phase 1 active small_molecule

Healthy Subjects (HS)

CT.gov ↗
NCT07032298
SSGJ-612

Phase 1 active small_molecule

Advanced Malignant Tumors

CT.gov ↗
NCT07038005
SPGL008

Phase 1 active small_molecule

Advanced Malignant Tumors

CT.gov ↗
NCT07039669
611

Phase 3 active small_molecule

Pulmonary Disease, Chronic Obstructive (COPD)

CT.gov ↗
NCT07042113
new formulations of 611

Phase 1 active small_molecule

Atopic Dermatitis

CT.gov ↗
NCT07042126
611

Phase 3 active small_molecule

Dermatitis, Atopic

CT.gov ↗
NCT07057726
SSS39

Phase 1 active small_molecule

Safety and Tolerability in Healthy Volunteers

CT.gov ↗
NCT07058779
SSS55

Phase 1 active small_molecule

Safety Issues

CT.gov ↗
NCT07065136
627

Phase 1 active mab

Healthy Subjects (HS)

CT.gov ↗
NCT07080931
5% minoxidil foam

Phase 3 active small_molecule

Androgenetic Alopecia

CT.gov ↗
NCT07082842
HEC585

Phase 3 active small_molecule

Idiopathic Pulmonary Fibrosis (IPF)

CT.gov ↗
NCT07099118
HEC169584 capsule

Phase 1 active small_molecule

Non - Alcoholic Steatohepatitis

CT.gov ↗
NCT07102251
HEC-007 injection

Phase 1 active small_molecule

Healthy Subjects

CT.gov ↗
NCT07171606
SSGJ-706

Phase 2 active small_molecule

First-line Advanced NSCLC Patients

CT.gov ↗
NCT07185269
626

Phase 2 active small_molecule

Systemic Lupus Erythematosus (SLE)

CT.gov ↗
NCT07211165
[14C]Clifutinib

Phase 1 completed small_molecule

Healthy Adult Male

CT.gov ↗
NCT07233850
SSGJ-706+XELOX

Phase 2 active small_molecule

Gastric/Gastroesophageal Junction Adenocarcinoma

CT.gov ↗
NCT07261644
608 dose

Phase 3 active small_molecule

Ankylosing Spondylitis

CT.gov ↗
NCT07341672
Clifutinib

Phase 1 active small_molecule

Healthy Adult Subject

CT.gov ↗
NCT07349329
608

Phase 3 active small_molecule

Axial Spondyloarthritis, Non-Radiographic

CT.gov ↗
NCT07376200
HEC-151 Injection

Phase 1 active small_molecule

Healthy Adult Male

CT.gov ↗
NCT07445308
SPGL008

Phase 2 active mab

NMIBC

CT.gov ↗
NCT07447843
Redefine

Unknown active other

Obesity & Overweight

CT.gov ↗
NCT07457294
1% Clascoterone Cream

Phase 3 active small_molecule

Acne Vulgaris

CT.gov ↗
NCT07487545
SSS67 Injection

Phase 1 active small_molecule

Healthy

CT.gov ↗
NCT07507513
627

Phase 2 active small_molecule

Ulcerative Colitis (UC)

CT.gov ↗
NCT07588646
HEC585

Phase 2 active small_molecule

Idiopathic Pulmonary Fibrosis

CT.gov ↗